Sartorius Ag · XETR:SRT
Sartorius — Q1 2025 Earnings Presentation
21 slides from Sartorius's earnings presentation, Apr 16, 2025
Slide 1: Investor Conference Call Q1 2025 Results
Investor Conference Call Q1 2025 Results Joachim Kreuzburg, Florian Funck, René Fáber Sartorius | Sartorius Stedim Biotech | April 16, 2025
Slide 2: Strong start to the year 2025
Sartorius Group Strong start to the year 2025 Group: ▪ Sales revenue growth 6.5% cc; book-to-bill ratio for both divisions well above 1 ▪ Substantial margin expansion driven by scale effects, product mix and PY efficiency program ▪ Strong cashflow; leverage ratio reduced as planned Q1 financial perf
Slide 3: Acquisition of MatTek to add innovative advanced cell model technology to the LPS portfolio
Sartorius Group Acquisition of MatTek to add innovative advanced cell model technology to the LPS portfolio Ashland, Mass., US (headquarters); Strategic rationale Bratislava, Slovakia ▪ A leading provider of human cell-based microtissues and 3D models for in vitro testing to accelerate preclinical d
Slide 4: Agenda
Agenda Sartorius Group Q1 2025 results | FY 2025 outlook Sartorius Stedim Biotech Group Q1 2025 results | FY 2025 outlook Questions & Answers 4
Slide 5: Significant profitable growth in Q1
Sartorius Group Significant profitable growth in Q1 Sartorius Group Q1 2024 Q1 2025 in % in % cc 1 in millions of € unless otherwise specified Sales revenue 820 883 +7.7 +6.5 Underlying EBITDA2 234 263 +12.2 Underlying EBITDA2 margin in % 28.6 29.8 +1.2pp Underlying EPS3 (ord.) in € 1.01 1.22 +21.5
Slide 6: Growth in all regions
Sartorius Group Growth in all regions EMEA Americas Asia | Pacific Sales by region Sales | € in millions Sales | € in millions Sales | € in millions in % +6.3% +8.1% +4.6% EMEA Americas 364 ~41% ~36% 341 321 288 190 198 €883m Asia | Pacific Q1 2024 Q1 2025 Q1 2024 Q1 2025 Q1 2024 Q1 2025 ~23% ▪ Grow
Slide 7: Bioprocess Solutions: Dynamic profitable growth
Sartorius Group Bioprocess Solutions: Dynamic profitable growth Sales revenue Underlying EBITDA & margin € in millions € in millions +9.7% cc +11.0% +17.0% 718 647 250 226 55 193 50 200 45 150 40 29.8 31.5 35 100 30 50 25 20 0 15 Q1 2024 Q1 2025 Q1 2024 Q1 2025 ▪ Strong recurring business with consu
Slide 8: Lab Products & Services: Continued soft market environment
Sartorius Group Lab Products & Services: Continued soft market environment Sales revenue Underlying EBITDA & margin € in millions € in millions -5.5% cc -4.4% -10.1% 173 165 41 37 24.0 22.6 Q1 2024 Q1 2025 Q1 2024 Q1 2025 ▪ Solid growth of recurring business with lab consumables and services ▪ Instr
Slide 9: Overproportionate increase of net profit and cash flow KPIs
Sartorius Group Overproportionate increase of net profit and cash flow KPIs Sartorius Group Q1 2024 Q1 2025 in % in millions of € unless otherwise specified Underlying net profit1,2 70 85 +21.4 ▪ Strong increase of operating cash flow due to higher earnings, lower tax payments and Reported net profi
Slide 10: Further deleveraging as planned; committed to investment-grade rating
Sartorius Group Further deleveraging as planned; committed to investment-grade rating Key financial indicators Net debt and net debt to underlying EBITDA Sartorius Group Dec. 31, Mar. 31, in millions of € unless otherwise specified 2024 2025 6.0 5,000 5.0 Equity ratio in % 38.6 38.0 4,000 4.0 3,000
Slide 11: Current situation regarding tariffs: No impact on competitive position; mitigating actions underway
Sartorius Group Current situation regarding tariffs: No impact on competitive position; mitigating actions underway to limit effects on profit Limited direct impact on top-line ▪ Mission-critical products spec'd into validated processes at customers; low price elasticity ▪ All players running global
Slide 12: 2025 guidance: Robust sales revenue growth and profitability
Sartorius Group 2025 guidance: Robust sales revenue growth and profitability Guidance 20251 Sales revenue growth Underlying EBITDA margin Sartorius Group + ~6% (+/- 2pp) ~29% to ~30% Bioprocess Solutions + ~7% (+/- 2pp) ~31% to ~32% Lab Products & Services + ~1% (+/- 2pp) ~22% to ~23% ▪ Capex ratio
Slide 13: Agenda
Agenda Sartorius Group Q1 2025 results | FY 2025 outlook Sartorius Stedim Biotech Group Q1 2025 results | FY 2025 outlook Questions & Answers 13
Slide 14: Significant profitable growth in Q1
Sartorius Stedim Biotech Group Significant profitable growth in Q1 Sartorius Stedim Biotech Group Q1 2024 Q1 2025 in % in % cc1 in millions of € unless otherwise specified Sales revenue 667 745 +11.7 +10.4 Underlying EBITDA2 191 229 +19.9 Underlying EBITDA2 margin in % 28.6 30.8 +2.2pp Underlying EP
Slide 15: Growth in all regions
Sartorius Stedim Biotech Group Growth in all regions EMEA Americas Asia|Pacific Sales by region Sales | € in millions Sales | € in millions Sales | € in millions in % +8.9% +13.8% +7.8% EMEA Americas ~ 42% ~ 37% 311 284 274 233 €745m 149 160 Asia|Pacific Q1 2024 Q1 2025 Q1 2024 Q1 2025 Q1 2024 Q1 20
Slide 16: Overproportionate increase of net profit and cash flow KPIs
Sartorius Stedim Biotech Group Overproportionate increase of net profit and cash flow KPIs Sartorius Stedim Biotech Group Q1 2024 Q1 2025 in % in millions of € unless otherwise specified Underlying net profit1,2 84 113 +34.5 ▪ Strong increase of operating cash flow due to higher earnings, lower tax
Slide 17: Further deleveraging as planned
Sartorius Stedim Biotech Group Further deleveraging as planned Key financial indicators Net debt and net debt to underlying EBITDA Sartorius Stedim Biotech Group Dec. 31, Mar. 31, 4,000 6.0 in millions of € unless otherwise specified 2024 2025 5.0 3,000 Equity ratio in % 48.7 48.3 4.0 2,000 3.0 Net
Slide 18: Current situation regarding tariffs: No impact on competitive position; mitigating actions underway
Sartorius Stedim Biotech Group Current situation regarding tariffs: No impact on competitive position; mitigating actions underway to limit effects on profit Limited direct impact on top-line ▪ Mission-critical products spec'd into validated processes at customers; low price elasticity ▪ All players
Slide 19: 2025 guidance: Robust sales revenue growth and profitability
Sartorius Stedim Biotech Group 2025 guidance: Robust sales revenue growth and profitability Guidance 20251 Sales revenue growth Underlying EBITDA margin Sartorius Stedim Biotech Group + ~7% (+/- 2pp) ~30% to ~31% ▪ Capex ratio of around 13% ▪ Net debt/ul. EBITDA to decrease to approx. 2.5 at year-en
Slide 20: Questions & Answers
Rts Questions & Answers x i
Slide 21: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee tha